Plain-English translation of NCT07322627 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Researchers are studying a specific genetic variation (called ALDH2 rs671) to understand how it might affect the course and outcome of esophageal cancer. This study will look at leftover tissue samples from patients already diagnosed with esophageal cancer to see if this genetic marker can predict how the cancer may develop and progress.
Many people, especially in East Asia, carry a genetic variation that makes it harder for their bodies to break down a toxic substance called acetaldehyde. This variation is linked to higher cancer risk, particularly when combined with alcohol use. Researchers want to understand whether this genetic marker can help predict which patients will have better or worse outcomes after an esophageal cancer diagnosis.
You likely qualify if…
You likely don't qualify if…
This is not a treatment trial — you are not receiving any new medication or undergoing any new procedures. Researchers will examine tissue samples you've already provided during your cancer diagnosis. Your participation involves allowing doctors to study your genetic information from those existing samples to see if the genetic variation affects your cancer prognosis.
AI-generated summary from trial data · Jun 7, 2026 · Not medical advice
Taiwan
Enrollment target
~700 participants
Started
December 2025
Primary completion
October 2027
Age range
18 Years – 99 Years
Sex
Male only
Last updated on clinicaltrials.gov in January 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Jang-Ming Lee
National Taiwan University Hospital
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.